secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2026-07-27T10:06:03+00:00
Accession:  0001193125-26-316766
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

argenx to acquire Forte Biosciences for $77/share (~$2.2B); adds anti-CD122 antibody FB102
--------------------------------------------------------------------------------

- argenx to acquire Forte Biosciences for $77/share in cash, total equity value ~$2.2B.
- Offer price represents ~86% premium to Forte's VWAP since positive Phase 1b vitiligo data on July 9, 2026.
- Acquisition adds first-in-class anti-CD122 antibody FB102 with clinical proof-of-concept in vitiligo and celiac disease.
- Forte board unanimously recommends; tender offer requires majority of shares tendered and HSR clearance.
- Supporting stockholders (directors/officers) owning ~1% of shares have agreed to tender.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312526316766/0001193125-26-316766-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312526316766/d31466d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-316766

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer